Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Nojomi, 2020
 
IRCT20180725040596N2
RCTlopinavir/ritonavirumifenovir (arbidol)COVID 19 hospitalizedsome concern
50/50 inconclusive
    RECOVERY, 2020
     
    NCT04381936
    RCTlopinavir/ritonavirstandard of careCOVID 19 hospitalizedsome concern
    1616/3424 inconclusive
    • inconclusive 3 % increase in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
    the trial Steering Committee concluded that there is no beneficial effect of lopinavir-ritonavir in patients hospitalised with COVID-19 and closed randomisation to that treatment arm
    SOLIDARITY (lopi/rito), 2020
     
    NCT04315948
    RCTlopinavir/ritonavirstandard of careCOVID 19 hospitalizedsome concern
    1399/1372 inconclusive
    • inconclusive 0 % increase in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias

    COVID-19 mild to moderate meta-analysis

    ELACOI (lopinavir/ritonavir), 2020
     
    NCT04252885
    RCTlopinavir/ritonavirstandard of careCOVID-19 mild to moderatesome concern
    21/7 inconclusive

      COVID-19 severe or critically meta-analysis

      Cao B, 2020
       
      ChiCTR2000029308
      RCTlopinavir/ritonavirstandard of careCOVID-19 severe or criticallysome concern
      99/100 suggested
      • inconclusive 31 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
      • suggested 94 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
      1 study excluded by filtering options (0 RCT / 1 OBS)

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).